[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples